CNS Pharmaceuticals (CNSP) Stock Price, News & Analysis

Company Overview

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

Key Stats

• Today's Range: $1.00 to $1.07
• 50-Day Range: $0.82 to $1.36
• 52-Week Range: $0.77 to $414.00
• Volume: 125,171 shs
• Average Volume: 685,126 shs
• Market Capitalization: $5.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.00
• Consensus Rating: Moderate Buy

CNS Pharmaceuticals Stock Analysis - MarketRank™

CNS Pharmaceuticals scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

CNS Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

CNS Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of CNS Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CNS Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.50% of the float of CNS Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

CNS Pharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CNS Pharmaceuticals has recently increased by 16.16%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CNS Pharmaceuticals does not currently pay a dividend.

Dividend Growth

CNS Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

13.50% of the float of CNS Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

CNS Pharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CNS Pharmaceuticals has recently increased by 16.16%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

3 people have searched for CNSP on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CNS Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.07% of the stock of CNS Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 14.02% of the stock of CNS Pharmaceuticals is held by institutions.

CNSP Stock Analysis - Frequently Asked Questions

How have CNSP shares performed this year?

CNS Pharmaceuticals' stock was trading at $6.02 at the start of the year. Since then, CNSP stock has decreased by 83.2% and is now trading at $1.01.
View the best growth stocks for 2025 here.

How were CNS Pharmaceuticals' earnings last quarter?

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) issued its quarterly earnings results on Thursday, May, 15th. The company reported ($1.58) EPS for the quarter.

When did CNS Pharmaceuticals' stock split?

CNS Pharmaceuticals's stock reverse split before market open on Friday, February 21st 2025. The 1-50 reverse split was announced on Wednesday, February 19th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 20th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

When did CNS Pharmaceuticals IPO?

CNS Pharmaceuticals (CNSP) raised $9 million in an initial public offering (IPO) on Friday, November 8th 2019. The company issued 2,100,000 shares at $4.00-$5.00 per share. Benchmark acted as the underwriter for the IPO.

How do I buy shares of CNS Pharmaceuticals?

Shares of CNSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CNS Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CNS Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), Broadcom (AVGO) and GE Aerospace (GE).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 6/06/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CNSP
• CIK: 1729427
• Web: www.cnspharma.com
• Phone: 800-946-9185
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $25.00
• High Stock Price Target: $25.00
• Low Stock Price Target: $25.00
• Potential Upside/Downside: +2,375.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3,748.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.85 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -515.32%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.82
• Quick Ratio: 1.82

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($35.66) per share
• Price / Book: -0.03

Miscellaneous

• Outstanding Shares: 5,462,000
• Free Float: 57,447,000
• Market Cap: $5.52 million
• Optionable: Not Optionable
• Beta: 2.67